Evidence map›Paper›PMID 31133718›Full record

ArticleScientific reports2019

Probe dependency in the determination of ligand binding kinetics at a prototypical G protein-coupled receptor.

Reggie Bosma, Leigh A Stoddart, Victoria Georgi, Monica Bouzo-Lorenzo, Nick Bushby, Loretta Inkoom, Michael J Waring, Stephen J Briddon, Henry F Vischer, Robert J Sheppard and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. New Chemical Biology Tools for the Histamine Receptor Family.Current topics in behavioral neurosciences · 2022
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Route to Prolonged Residence Time at the Histamine HJournal of medicinal chemistry · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 5 countries.

Reggie BosmaAmsterdam Institute for Molecules, Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Faculty of Science, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
Leigh A StoddartDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, NG7 2UH, UK.
Victoria GeorgiDrug Discovery, Bayer AG, Berlin, Germany.
Monica Bouzo-LorenzoDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, NG7 2UH, UK.
Nick BushbyIMED Operations, IMED Biotech Unit, AstraZeneca, Alderley Park, United Kingdom.ORCID http://orcid.org/0000-0002-9025-7015
Loretta InkoomAmsterdam Institute for Molecules, Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Faculty of Science, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
Michael J WaringMedicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Alderley Park, United Kingdom.
Stephen J BriddonDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, NG7 2UH, UK.
Henry F VischerAmsterdam Institute for Molecules, Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Faculty of Science, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
Robert J SheppardMedicinal Chemistry, Cardiovascular, Renal, and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Amaury Fernández-MontalvánDrug Discovery, Bayer AG, Berlin, Germany.ORCID http://orcid.org/0000-0001-9156-0000
Stephen J HillDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, NG7 2UH, UK.
Rob LeursAmsterdam Institute for Molecules, Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Faculty of Science, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands. r.leurs@vu.nl.
University of Nottingham · GBVrije Universiteit Amsterdam · NLAstraZeneca (United Kingdom) · GBAstraZeneca (Sweden) · SEAVL (France) · FRBayer (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-target binding kinetics are suggested to be important parameters for the prediction of in vivo drug-efficacy. For G protein-coupled receptors (GPCRs), the binding kinetics of ligands are typically determined using association binding experiments in competition with radiolabelled probes, followed by analysis with the widely used competitive binding kinetics theory developed by Motulsky and Mahan. Despite this, the influence of the radioligand binding kinetics on the kinetic parameters derived for the ligands tested is often overlooked. To address this, binding rate constants for a series of histamine H

Indexed as

Binding, CompetitiveCetirizineDatasets as TopicFluorescence Resonance Energy TransferFluorescent DyesHEK293 CellsHistamine H1 AntagonistsHumansLigandsMolecular ProbesOlopatadine HydrochlorideProtein BindingPyrilamineRadioligand AssayReceptors, Histamine H1TritiumCetirizineFluorescent DyesHistamine H1 AntagonistslevocetirizineLigandsMolecular ProbesOlopatadine HydrochloridePyrilamineReceptors, Histamine H1Tritium

Identifiers

PMID31133718
PMCPMC6536503
OpenAlexW2947170120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.